- Article
Patient Experience with Intranasal Esketamine in Treatment-Resistant Depression: Insights from a Multicentric Italian Study (REAL-ESKperience)
- Marco Di Nicola,
- Maria Pepe,
- Giacomo d’Andrea,
- Ilaria Marcelli,
- Mauro Pettorruso,
- Ileana Andriola,
- Stefano Barlati,
- Matteo Carminati,
- Carlo Ignazio Cattaneo and
- Massimo Clerici
- + 20 authors
Background. Treatment-resistant depression (TRD) is a prevalent, high-burden disorder. Esketamine nasal spray (ESK-NS) has been approved for, T.R.D.; and efficacy has been observed in both clinical trials and real-world studies. However, observations...

